Glenmark’s consolidated revenue rises 14.39 percent

Glenmark Pharmaceuticals Limited announced its financial results for the second quarter (2Q) ended September 30 of financial year 2018-19. In the 2Q, Glenmark’s consolidated revenue was at Rs 25,813.32 million as against Rs 22,565.90 million, recording an increase of 14.39 percent. Consolidated net profit was at Rs 4140.00 million for the quarter ended September 30, 2018 as compared to Rs 2141.20 million in the previous corresponding quarter, registering an increase of 93.30 percent.

Consolidated EBITDA was at Rs 5799.85 million in the quarter ended September 30, 2018 as against Rs 4181.22 million in the previous corresponding quarter, an increase of 38.71 percent. During the 2Q, the company had a one-time exceptional income of Rs 1671.82 million.

Glenmark’s other revenue was at Rs 771.26 million for the second quarter of FY 2018-19, as against Rs 253.64 million in the previous corresponding quarter, recording an increase of 204.07 percent. Other revenue includes out-licensing income on account of the exclusive license agreement signed with Harbor Biomed for the Greater China territory to develop, manufacture, and commercialize GBR 1302.

“We continue to invest in building and advancing our R&D pipeline of innovative assets and specialty products, which will spur long-term sustainable growth.”

Glenn Saldanha
Chairman and Managing Director,
Glenmark Pharmaceuticals